

04 OCT 1996

Express Lail Number: EH 608540192 US

		·					
FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMAN (REV 5-93)		RK OFFICE ATTORNEY'S DOCKET NUMBER					
(REY )->)		96.1252.US					
TRANSMITTAL LETTER TO THE UNITED STATE							
•	ED OFFICE (DO/EO/US)	US APPLICATION NO. (IF KNOWN, SEE 37 CFR § 1.5)					
	NG UNDER 35 U.S.C. 371	08/722045					
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE						
PCT/IE 95/00025	April 6, 1995	April 6, 1994					
TITLE OF INVENTION							
EFFERVESCENT PHARMACEUTICAL FORMULA	TIONS CONTAINING CONTROLLED I	RELEASE BIODEGRADABLE MICROCAPSULES					
APPLICANT(S) FOR DO/EO/US							
Virginia Freeman							
Zebunnissa Ramtoola							
Applicant herewith submits to the United States D	Designated/Elected Office (DO/EO/US	s) the following items and other information:					
1. This is a FIRST submission of ite	ms concerning a filing under 35 U.S.	C. 371.					
. —	ENT submission of items concerning						
	• •	C. 371(f) at any time rather than delay					
		J.S.C. 371(b) and PCT Articles 22 and 39(1).  by the 19th month from the earliest claimed priority date.					
<del></del> .		, and a second and a					
5. \( \sum \) A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
. —	herewith (required only if not transn	nitted by the International Bureau).					
	smitted by the International Bureau.	Inited States Receiving Office (RO/US)					
c. is not required, as the application was filed in the United States Receiving Office (RO/US)							
6. A translation of the International A	Application into English (35 U.S.C. 3	71(c)(2)).					
7. Amendments to the claims of the	International Application under PCT	Article 19 (35 U.S.C. 371(c)(3))					
a. are transmitte							
	insmitted by the International Bureau.						
	c. have not been made; however, the time limit for making such amendments has NOT expired.						
d. have not been made; however, the time limit for making such amendments has NOT expired.  have not been made and will not be made.							
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)4)).							
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11. to 16. below concern other document(s) or information included:  11.							
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13. A FIRST preliminary amendment.  A SECOND or SUBSEQUENT preliminary amendment.		I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Invoice No. EH 608540192 US in an envelope addressed to:					
		Commissioner of Patents					
14. A substitute specification.		and Trademarks					
	/	Washington, D.C. 20231					
15. A change of power of attorney and	A change of power of attorney and/or address letter.  on this 4th day of October 1996.						
16. Other items or information: A cop		Janela Brailich 10/4/96					
Preliminary Examination Report	is enclosed for your conveniece	Pamela Scarbrough Date					

U.S. APPLICATION NO	ICATION NO. (If known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER:			
		PCT/IE 95/00025		96.1252.US			
17. The following fees are submitted:			CALCULATIONS	PTO USE ONLY			
Basic National Fee (37 CFR 1.492(a)(1)-(5)):				<u> </u>	<u> </u>		
	t has been prepared by the E	ļ					
·							
International preliminary examination fee paid to USPTO (37 CFR 1.482)\$680.00							
	nal preliminary examination						
but international search fee paid to USPTO (37 CFR 1.445 (a)(2)) \$750.00							
Neither international preliminary examination fee (37 CFR 1.482) nor							
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1010.00							
International	preliminary examination fee						
	satisfied provisions of PCT						
	•						
ENTER APPROPRIATE BASIC FEE AMOUNT				\$ 880.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30							
	or furnishing the oath or declar t claimed priority date (37 Cl		20 [ ] 30		]		
monuis from the earliest	cianned priority date (37 Ci						
Claims	Number Filed	Number Extra	Rate				
Total Claims	20 -20=	0	X \$22.00	\$ 0.00	1		
Independent Claims	4 - 3=	0	X \$78.00	\$ 78.00			
Multiple dependent clair	ms(s) (if applicable)	•	+ \$250.00	\$ 0.00			
	TOTAL OF ABOVE	CALCULATIONS		\$			
	ng by small entity, if applica		y statement	\$			
must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).							
				\$ 958.00			
Processing fee of \$130.00 for furnishing the English translation later than 20 30				•			
months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	-		
TOTAL NATIONAL FEE =				\$ 958.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 1.21(h)). \$40.00 per property				\$			
TOTAL FEES ENCLOSED =				\$ 958.00			
_		101112122	B. (CDODD)	Amount to be refunded:	\$		
				charged:	T		
	·				•		
a. A check in the amount of \$ 958.00 to cover the above fees is enclosed.							
b. Please charge my Deposit Account No. <u>05-0670</u> in the amount of to cover the above fees.							
A duplicate copy of this sheet is enclosed.							
The Commissioner is homely sutherized to shore any additional feet which were be required as small and							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit and overpayment to Deposit Account No. 05-0670. A duplicate copy of this sheet is enclosed.							
overpayment to Deposit Account no. <u>vortore</u> . A dupiteate copy of unit silect is cholosed.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR							
1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
CEND ALL CORRESPONDENCE TO				$M$ , ( $\subset$			
SEND ALL CORRESPONDENCE TO:			SIGNATURE	<del>-</del>			
Mary L. Sever	rson, Ph.D.			JIGIMIPORE			
ELAN PHARMACEUTICAL RESEARCH CORPORATION				Mary L. Severson			
1300 Gould Drive				NAME	_		
Gainesville, GA 30504 770-534-8239 34,927							
770-534-8239 <u>34,927</u> REGISTRATION NUMBER							
				ALCIOTALITON NOME			